reason report
recap lt outlook still lever grow bio-molecular
bottom line remain outperform-r given
view compani life scienc tool lst leader
unmatch scale reach lab combin number
growth product serv key end-market grow
consolid posit trade today softer-than-
expect guid back-half load almost in-lin
double-digit growth howev china slow low-singl digit
last quarter amid tougher comp slower releas capit fund
instrument industri appli end-market declin mid-singl
digit double-digit comp analyt technolog declin
y/i continu deceler growth vs strong continu
see posit upsid specialti diagnost sd lab product
servic lp post stronger-than-expect organ
growth segment remain op pt move
shift ev/ebitda comp valuat
continu benefit grow bioprocess posit
market get increasingli lever biomolecul
bioprocess busi continu benefit end-market
growth share captur contribut strongli expect growth
continu believ volum revenu segment expand
market benefit end-to-end coverag especi
patheon brammer acquisit continu contribut integr
qtr lt outlook china remain strong point
strong quarter north america europ msd hsd growth
respect howev china apac region lsd growth
step prior quarter hsd respect
invest china recent open pharma biotech
solut center shanghai manag highlight slower releas
fund capit purchas countri contribut slower
growth pull apac region perform whole
finish year china comp
continu expand presenc countri
like conserv guidanc offer beat rais potenti
throughout year call guid top-lin organ growth
 adj ep growth highlight continu cost leverag
busi restructur debt manag suggest
potenti conservat guidanc rang highlight similar
guid last year increas throughout year end-market
visibl believ organ growth guid conserv
updat model reflect quarter guid
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquir view
consolid sizabl portion lst market patheon acquisit close
brammer also close believ potenti consolid contract
develop manufactur organ industri long term view
posit given sheer scale reput presenc lst market biopharma
academ channel industrial/environment diagnost deliv manag
forecast grow solidifi presenc emerg market asia-pacif
china revenu continu strength biopharma end-market view
sign slow near term inorgan growth continu remain
key prioriti next five year capit deploy
share current trade ev/ebitda slightli behind large-
mid-cap tool averag ev/ebitda
given impress growth deliv leverag biolog drug discoveri
develop product china emerg market tailwind still continu believ
continu hold posit lead lab tool suppli provid like
continu post strong growth expect trade line large- mid-cap tool
averag deliv ev/ebitda deriv price target appli
multipl ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report svb leerink estim
